关键词: 内囊预警综合征; 尤瑞克林注射液; 基质金属蛋白酶9; 治疗结果

Abstract: Objective To investigate the effects of Kallikrein on serum matrix metalloproteinase-9(MMP-9) and its clinical efficacy in patients with stroke coming from capsular warning syndrome.Methods Thirty-one patients with stroke coming from capsular warning syndrome were randomly divided into control group(n=15) and treatment group(n=16). Each group was consistently given 14 days basical treatment, treatment group was given Kallikrein else. The serum levels of MMP-9 were detected before and after treatment. All patients' never function was assessed by National Institutes of Health Stroke Scale(NIHSS) and Barthel Index(BI) at admission and at 3 months after admission.Results Compared with that at admission, NIHSS decreased and BI increased at 3 months, there was statistical deference in two groups(each P＜0.001), and treatment group has lower NIHSS and higher BI (P＜0.001). After treatment, obvious decrease of serum MMP-9 concentration was seen in both groups comparing with non-treatment(each P＜0.01), and treatment group was lower than control group(P＜0.01).Conclusion Kallikrein can improve functional neurological recovery and reduce the serum level of MMP-9 in patients with stroke coming from capsular warning syndrome.

Key words: Capsular warning syndrome; Kallikrein; Matrix metalloproteinase-9; clinical Treatment outcome